<DOC>
	<DOCNO>NCT01295788</DOCNO>
	<brief_summary>The investigator hypothesize REAL-Time Continuous Glucose Monitoring ( RT-CGM ) effective introduce child adolescent establish diabetes time start pump therapy . This randomize controlled trial compare effectiveness simultaneous v delay introduction RT-CGM child adolescent type 1 diabetes start insulin pump therapy .</brief_summary>
	<brief_title>Timing Initiation Continuous Glucose Monitoring Established Pediatric Diabetes ( The CGM TIME Trial )</brief_title>
	<detailed_description>REAL-Time Continuous Glucose Monitoring ( RT-CGM ) improve diabetes control adult type 1 diabetes . However , study RT-CGM child adolescent mostly negative . The lack effectiveness pediatric population appear directly relate adherence RT-CGM , i.e. , willingness child teen wear use technology . Most previous RT-CGM study focus experienced pump user child new-onset diabetes . At time pump initiation , child adolescent live diabetes ( parent ) highly motivate make change diabetes management take additional responsibility improve diabetes control lifestyle , two primary reason initiate pump therapy pediatric population . The investigator hypothesize readiness making change diabetes management great time pump initiation six month pump start . Further , investigator hypothesize readiness change time RT-CGM initiation predict future adherence RT-CGM effectiveness .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : Males female age 518 year old . Established T1D diagnosis minimum one year . Na√Øve CSII therapy ready start CSII Veo pump ( Medtronic ) . Willing use RTCGM randomly assign either simultaneous delayed RTCGM initiation . Regular diabetes follow one 5 participate site . Internet access home ( upload RTCGM data ) . Parent ( ) legally acceptable representative able speak read English French . Ability subject parent ( ) legally acceptable representative participate aspect clinical trial . Written informed consent must obtain document , assent child &lt; 14 year age . Exclusion Criteria Conditions opinion investigator may interfere subject 's ability participate study . Has receive oral and/or intravenous steroid therapy ( indication , dose and/or duration ) 2 separate occasion past 12 month . Use inhale and/or topical steroid therapy last 12 month exclude subject . Prior use RTCGM 50 % time past 6 month . Prior enrollment current study . Current enrollment another intervention trial .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>